Report Phase 3 data for the BROOKLYN trial
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 22 Jan 2024
- Due
- 30 Sep 2024
- Delivered
- 29 Jul 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“3Q 2024: BROOKLYN”
What we found
Evidence strength A What the grades mean
NewAmsterdam reported BROOKLYN Phase 3 topline data on July 29, 2024, within Q3 2024 deadline, meeting primary endpoint.
-
A Current Report on Form 8-K - BROOKLYN Trial Results SEC filing documenting announcement of positive BROOKLYN topline results July 29, 2024
-
D NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Company press release announcing positive topline BROOKLYN data on July 29, 2024
Checked 22 Sep 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Report
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you NewAmsterdam Pharma Co N.V.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-NAMSW-000039 · Corrections policy